Mastocytosis: The new differential diagnosis of CD30-positive neoplasms

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 732-733

  Maric, Irina ^a   Calvo, Katherine R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CD11B ANTIGEN; CD2 ANTIGEN; CD30 ANTIGEN; CD59 ANTIGEN; CD63 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; TRYPTASE; VALINE;

ASCITES; BONE MARROW BIOPSY; BONE MARROW CELL; CELL INFILTRATION; CODON; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE MUTATION; HEPATOSPLENOMEGALY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA CELL LINE; LIVER FUNCTION; MALABSORPTION; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; NEOPLASM; NOTE; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR CELL;

ANTIGENS, CD30; HUMANS; LEUKEMIA, MAST-CELL; MASTOCYTOSIS, SYSTEMIC;

EID: 79955050800     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.561389     Document Type: Note

References (8)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2010;113:5727-5736.
3. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372. (Pubitemid 44497521)
4. Escribano L, Díaz Agustín Beatriz, Bravo P, et al. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma 1999;35:227-235.
5. Escribano L, Garcia Montero AC, Núñez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am 2006;26:535-547. (Pubitemid 44247538)
6. Núñez-López R, Escribano L, Schernthaner GH, et al. Over-expression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br J Haematol 2003;120:257-265. (Pubitemid 36194174)
7. Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011;52:740-744.
8. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2010 Dec 24. [Epub ahead of print]